Our People

We are an eclectic mix of backgrounds and specialties, female strong and multi-faceted. We are a team of doctors, scientists, genetic counselors, lab technicians, artists, ocean-lovers and science geeks. We are people. Looking for answers using the most advanced technology and quality processes in the diagnostics industry.

But with all our differences, we have one thing in common: we view every sample that comes into our lab as a life, someone’s dad, sister, best friend. We understand that attached to every sample is a person with a family to raise; a team to coach; a department to lead.

This is what gets us out of bed each day. We love what we do collectively as a team with all our differences because what brings us together is this life-changing work. Every day we are reminded why we are here.

Ambry Genetics Employee Statistics

Our Executive Team

Kiyotaka Fujii

Kiyotaka Fujii

President, Global Healthcare, Konica Minolta & Chairman, Ambry Genetics
Kiyotaka Fujii leads Konica Minolta’s global healthcare business, which focuses on the advancement of Precision Medicine and Medical Diagnostics. Fujii is also Chairman of Ambry Genetics and Invicro, a biomarker imaging CRO based in Boston.

Fujii’s extensive business career ranges from medical services, information technology, and consumer products to investment banking. Fujii has held several Japan CEO positions with top global companies since 1997, including SAP, Louis Vuitton, Cadence Design Systems and Quintiles Transnational. From 2012 to 2015, he served at Olympus as the first independent board member to re-build its governance and businesses.

From 1986 to 1993, Fujii held the role as the first Japanese M&A investment banker in New York with Credit Suisse First Boston and Goldman Sachs. Fujii began his career with McKinsey as the first hire from a Japanese University.

Aaron Elliott, PH.D.

Aaron Elliott, PH.D.

Chief Executive Officer, Konica Minolta Precision Medicine
Dr. Aaron Elliott is responsible for driving execution across all Konica Minolta Precision Medicine (KMPM) business units, which include Ambry Genetics, Invicro and KMPM-Japan.

Prior to his role as CEO of KMPM, Dr. Elliott was at Ambry Genetics leading the company through 13 years of trailblazing milestones. He joined Ambry in 2008 in the research and development department working closely on the development of comprehensive molecular diagnostic tests. An innovator in complex genetic testing, Dr. Elliott has been involved in the conception and implementation of many of the diagnostic industry first to market tests and technologies including the first commercial NGS assay, CLIA/CAP Exome test and hereditary cancer panels among others. Dr. Elliott and the Ambry team were instrumental in mounting a creative defense in the groundbreaking University of Utah Research Foundation, et al., v. Ambry Genetics Corporation case which ended the monopoly of BRCA testing in the United States.

Search Results

Start your search...